ID Protein targeted cancer immunotherapy. The invention provides a cell-based attenuated live tumor cell vaccine that safely produces broad cellular tumor-specific immunity, protects against tumor formation in prophylactic tumor models, and in combination with the clinically relevant immune modulator s such as antibodies to CTLA-4 or antibodies to PD-L1 can destroy established tumors in mammals.